31st week of 2013 patent applcation highlights part 50 |
Patent application number | Title | Published |
20130196863 | METHOD OF DETERMINING CHROMATIN STRUCTURE - A method of determining chromatin structure is described. The method comprises the steps of (i) fragmenting a nucleotide sequence at multiple HSs; and (ii) analysing fragments formed in step (i) from a plurality of sequences. In a preferred aspect, the present invention provides a method of determining chromatin structure in a nucleic acid sample comprising the steps of (i) treating the sample to fragment the nucleic acid therein at multiple HSs; and (ii) analysing fragments formed in step (i) from a plurality of genes. | 2013-08-01 |
20130196864 | DESIGN, SYNTHESIS AND ASSEMBLY OF SYNTHETIC NUCLEIC ACIDS - Methods of synthesizing oligonucleotides with high coupling efficiency (>99.5%) are provided. Methods for purification of synthetic oligonucleotides are also provided. Instrumentation configurations for oligonucleotide synthesis are also provided. Methods of designing and synthesizing polynucleotides are also provided. Polynucleotide design is optimized for subsequent assembly from shorter oligonucleotides. Modifications of phosphoramidite chemistry to improve the subsequent assembly of polynucleotides are provided. The design process also incorporates codon biases into polynucleotides that favor expression in defined hosts. Design and assembly methods are also provided for the efficient synthesis of sets of polynucleotide variants. Software to automate the design and assembly process is also provided. | 2013-08-01 |
20130196865 | METHOD FOR SELECTING AN IPS CELL - This application relates to a method for selecting an induced pluripotent stem cell (iPS), the method comprising: selecting an iPS cell that expresses a gene in the Dlk1-Dio3 cluster from a population of iPS cells. The method further comprises: comparing the gene expression profile determined for an iPS cell with the gene expression profile determined for an embryonic stem cell; identifying a gene that is differentially expressed in the embryonic stem cell as compared to the iPS cell; and selecting the desired iPS cell from a population of iPS cells. | 2013-08-01 |
20130196866 | EXPRESSION OF ETS RELATED GENE (ERG) AND PHOSPHATASE AND TENSIN HOMOLOG (PTEN) CORRELATES WITH PROSTATE CANCER CAPSULAR PENETRATION - The disclosure provides methods for characterizing a prostate cancer sample by detecting expression of ERG, PTEN or both, changes in which relative to a normal control are shown herein to be correlated with prostate cancer capsular penetration and more aggressive forms of prostate cancer. Such methods are useful for the prognosis of prostate cancer capsular penetration and for making treatment decisions in patients with prostate cancer that has penetrated the capsule. Also provided are kits that can be used with such methods. | 2013-08-01 |
20130196867 | COMBINATORIAL POST-TRANSLATIONALLY-MODIFIED HISTONE PEPTIDES, ARRAYS THEREOF, AND METHODS OF USING THE SAME - The present invention generally relates to combinatorial post-translationally-modified histone peptides and arrays thereof. The invention further relates to methods of using the same. | 2013-08-01 |
20130196868 | METHODS AND ALGORITHMS FOR AIDING IN THE DETECTION OF CANCER - A method of data interpretation from a multiplex cancer assay is described. The aggregate normalized score from the assay is transformed to a quantitative risk score quantifying a human subject's increased risk for the presence of cancer as compared to the known prevalence of the cancer in the population before testing the subject. | 2013-08-01 |
20130196869 | MICRORNA PROFILING FOR DIAGNOSIS OF DYSPLASTIC NEVI AND MELANOMA - Provided herein are methods for miRNA profiling for the diagnosis, prognosis, and management of melanoma and differentiation of melanoma from nevi. | 2013-08-01 |
20130196870 | SYSTEMS AND METHODS USING BIOMARKER PANEL DATA - Embodiments of the disclosure are related to systems and methods for utilizing biomarker panel data and related medical devices and methods, amongst other things. An embodiment can include a method of screening patients. The method can include quantifying levels of one or more of a panel of biomarkers in a biological sample of a patient. The method can further include analyzing the quantified levels. In some embodiments, the panel of biomarkers includes at least two selected from the group consisting of CRP, SGP-130, sIL-2R, sTNFR-II, IFNg, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. In an embodiment, the disclosure can include a method of diagnosing a patient. The method can include quantifying levels of one or more of a panel of biomarkers in a biological sample of a patient. The method can further include diagnosing the patient based at least in part on the quantified levels. In some embodiments, the panel of biomarkers includes at least two selected from the group consisting of CRP, SGP-130, sIL-2R, sTNFR-II, IFNg, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. Other embodiments are also included herein. | 2013-08-01 |
20130196871 | Fibronectin Binding Domains with Reduced Immunogenicity - Fibronectin type III ( | 2013-08-01 |
20130196872 | PATHOGEN DETECTION - Pathogens are detected through the use of mutation-resistant ligands. | 2013-08-01 |
20130196873 | METHOD OF ANALYSING A BLOOD SAMPLE OF A SUBJECT FOR THE PRESENCE OF A DISEASE MARKER - The present invention relates to a method of analyzing a blood sample of a subject for the presence of a disease marker, said method comprising the steps of a) extracting nucleic acid from anucleated blood cells in said blood sample to provide an anucleated blood cells-extracted nucleic acid fraction, and b) analysing said anucleated blood cells-extracted nucleic acid fraction for the presence of a disease marker, wherein said disease marker is a disease-specific mutation in a gene of a cell of said subject, or wherein said disease marker is a disease-specific expression profile of genes of a cell of said subject. | 2013-08-01 |
20130196874 | SENSOR FOR DETECTION AND IDENTIFICATION OF ANALYTES AND A METHOD THEREOF - The present invention discloses a method and sensor for detection and identification of analytes such as foreign material or DNA and RNA in particular in low concentration. The sensitivity of the method allows the detection of few molecules (down to a single one) independent on the concentration of the sample. There is provided a sensor for analyte(s) detection in a fluid sample. The sensor comprises at least one tube-like member carrying an arrangement of probes patterned thereinside. | 2013-08-01 |
20130196875 | CELL CHARACTERISATION - The present invention concerns the finding that non-coding RNA profiles can be exploited as a means of monitoring, assessing, comparing, establishing and/or determining certain cell characteristics and/or profiles. Accordingly, the invention provides the use of non-coding RNA molecules for characterising and/or profiling cells. | 2013-08-01 |
20130196876 | DIFFERENTIAL DIAGNOSIS OF PANCREATIC ADENOMAS - The invention relates to a method for the diagnosis of pancreatic adenomas, to biomarkers for use in said method, to kits for carrying out the method, and to the use of said method for detecting pancreatic adenomas. The following markets are used: KCNABT, CIORF77, SPSB2, MED9, STK40, ITGB3BP, SCEL, PDPK1, DUSP15, MED19, NAP1L3, TMOD3, CSPP1, TMOD2, INPP5A and IGHG. | 2013-08-01 |
20130196877 | IDENTIFICATION OF MULTI-MODAL ASSOCIATIONS BETWEEN BIOMEDICAL MARKERS - The present invention relates to a method for identifying multi-modal associations between biomedical markers which allows for the determination of network nodes and/or high ranking network members or combinations thereof, indicative of having a diagnostic, prognostic or predictive value for a medical condition, in particular ovarian cancer. The present invention further relates to a biomedical marker or group of biomedical markers associated with a high likelihood of responsiveness of a subject to a cancer therapy, preferably a platinum based cancer therapy, wherein said bio-medical marker or group of biomedical markers comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 8, 19, 20 or all markers selected from PKMYT1, SKIL, RAB8A, HIRIP3, CTNNB1, NGFR, ZCCHC11, LSP1, CD200, PAX8, CYBRD1, HOXC11, TCEAL1, FZD10,FZD1, BBS4, IRS2, TLX3, TSPAN2, TXN, and CFLAR. Furthermore, an assay for detecting, diagnosing, graduating, monitoring or prognosticating a medical condition, or for detecting, 1 diagnosing, monitoring or prognosticating the responsiveness of a subject to a therapy against said medical condition, in particular ovarian cancer, is provided, as well as a corresponding method for classifying a subject comprising and a medical decision support system. | 2013-08-01 |
20130196878 | APPARATUS AND METHOD FOR DETECTING MULTIPLEX TARGET NUCLEIC ACIDS IN REAL TIME - The present invention relates to an apparatus and method for simultaneously detecting various types of target nucleic acids in real time, whereby various types of target nucleic acids can be simultaneously detected in real time to allow manufacturing an apparatus in the shape of a chip, and to efficiently detect a plurality of species of nucleic acids in a small space. | 2013-08-01 |
20130196879 | ASSAY SYSTEM - The invention provides a method of forming a plurality of re-constitutable doses of at least one drug in a plurality of wells, the method including the steps of (i) placing a known amount of said drug in a suitable carrier to form a first composition having a known concentration (ii) placing at least two selected amounts of that first composition into individual wells and (iii) converting the first composition into a transportable form that can later be converted into a second composition having a known concentration and (iv) sealing the wells. | 2013-08-01 |
20130196880 | PATTERNED DEVICES AND METHODS FOR DETECTING ANALYTES - Disclosed herein are devices for the detection of target molecules and methods for their use and production. The disclosed devices may include optically decipherable patterns that facilitate an understanding of binding events between a target molecule and a detection molecule. In one example, a device includes a macroscopic pattern constructed using microscopic elements that can be chromogenically developed to memorialize a binding event. In another example, a device includes characters that can be chromogenically developed using an automated slide staining instrument to memorialize a binding event. | 2013-08-01 |
20130196881 | SUGAR CHAIN ARRAY - A sugar chain array containing a sugar chain immobilized thereon for detecting binding between an analyte and a sugar chain, and a sugar chain array having the sugar chain immobilized thereon that is capable of inhibiting non-specific adsorption and binding of an analyte without having to coat the array with an adsorption inhibitor. A specific sugar chain is immobilized on the array, and is useful for detecting binding between the sugar chain and an analyte, such as a pathogen of an infectious disease or an excretion thereof. In addition, in the array, when a base material is coated with a polymeric compound having a unit having a primary amino group, a unit for maintaining hydrophilicity, and a unit having a hydrophobic group, the sugar chain is immobilized efficiently and non-specific adsorption and binding of the analyte can be effectively inhibited. | 2013-08-01 |
20130196882 | FLOW ADDITIVE FOR LIGHT OR HEAVY CRUDE OILS, USE OF THE ADDITIVE AND PROCESS TO IMPROVE THE EXTRACTION, PUMPING AND/OR TRANSPORT OF LIGHT OR HEAVY CRUDE OILS - The present invention refers to a flow additive useful to improve the extraction and displacement of light or heavy crude oils, which comprises an aqueous emulsion containing hollow or solid synthetic microspheres, a component able to alter the superficial tension, high molecular weight polyelectrolytes, a glycol-type antifreeze and fluidity improvement agent and a thickening agent. The additive according to the present invention improves the flow of crude oil pumped from the wells to storage tanks and also cleans and prevents against incrustations of paraffin and heavy hydrocarbons derived from the perforation of the petroleum wells drilling, even though in low temperatures (below of 0 Celsius degrees). | 2013-08-01 |
20130196883 | CELLULOSE NANOWHISKERS IN WELL SERVICES - A method is provided for use in various well services, the method including the steps of: (a) forming or providing a well fluid comprising cellulose nanowhiskers; and (b) introducing the well fluid into a well. The method can be used, for example, for increasing the strength of a cement, for increasing the viscosity of a water-based well fluid, such as for a kill pill, a fracturing fluid, a gravel packing fluid. | 2013-08-01 |
20130196884 | Downhole Chemical Delivery For Oil And Gas Wells - A method of reducing the cost and environmental impact of chemicals used in hydraulic fracturing is to use a proppant that is coated with at least two chemicals, where each of those chemicals are useful in treating a well. By coating at least two chemicals onto the proppant the amounts of chemicals required to treat a well are reduced by delivering the chemicals to only the areas that require treatment. Additionally mixing issues are avoided as only a single proppant or substrate is used in the well. | 2013-08-01 |
20130196885 | USE OF ENVIRONMENTALLY FRIENDLY SOLVENTS TO REPLACE GLYCOL-BASED SOLVENTS - A method for replacing glycol-based mutual solvents in an oil field application comprising: obtaining an alternative solvent and solvent blends and replacing all or a portion a glycol-based mutual solvent, which forms a component of an oil field formulation, with the alternative solvent or solvent blends, wherein the oil field formulation can be utilized in an oil field application. | 2013-08-01 |
20130196886 | SURFACTANT SYSTEMS FOR ENHANCED OIL RECOVERY - The invention relates to a hydrocarbon recovery composition comprising a combination of an internal olefin sulfonate and an alkoxy glycidyl sulfonate, more specifically a hydrocarbon recovery composition comprising surfactant and water, wherein the surfactant comprises a combination of an internal olefin sulfonate with a chain length of greater than C20 and an alkoxy glycidyl sulfonate selected from an ethoxylated glycidyl sulfonate and a propoxylated glycidyl sulfonate. Further, the invention relates to a method of treating a hydrocarbon containing formation, comprising (a) providing a hydrocarbon recovery composition to at least a portion of the hydrocarbon containing formation, wherein the composition comprises a blend of an internal olefin sulfonate and an alkoxy glycidyl sulfonate; and (b) allowing the composition to interact with hydrocarbons in the hydrocarbon containing formation. | 2013-08-01 |
20130196887 | LUBRICANT COMPOSITION AND METHODS OF MANUFACTURE THEREOF - Disclosed herein is a lubricant composition comprising a hydrocarbon oil; inorganic particles; and molybdenum disulfide; the molybdenum disulfide being dispersed in the soybean oil. Disclosed herein too is a lubricant composition comprising a base oil; inorganic particles; and metal disulfide particles; the metal disulfide particles being dispersed in the base oil in the presence of an electrical field and a mechanical field. Disclosed herein too is a method comprising agitating a composition to form a lubricating composition; the composition comprising molybdenum disulfide, inorganic particles and a base oil; the agitating being conducted in the presence of a magnetic field that is greater than the earth's field, an electrical field or a combination comprising the magnetic field and the electrical field. | 2013-08-01 |
20130196888 | ENGINE LUBRICANT - A lubricant composition includes: (a) one or more base oils, (b) at least one comb polymer formed by a polyalkyl(meth)acrylate main chain, and hydrocarbon side chains including at least 50 carbon atoms, (c) at least one nitrogen-containing organic friction modifier chosen from the optionally alkoxylated fatty amines, fatty amides or imides obtained by the condensation of fatty amines and carboxylic acids, alone or in a mixture, (d) optionally, one or more organometallic organomolybdenum-type friction modifiers. This is used for the lubrication of 4-stroke gasoline or diesel engines of light vehicles, preferentially of hybrid vehicles. | 2013-08-01 |
20130196889 | AQUEOUS CLEANING AGENT - An aqueous detergent according to the invention contains substantially no polyalkylene glycol, but contains a salt of at least one of the following carboxylic acids A, B and C: A: an aliphatic monobasic carboxylic acid having a total carbon number of 9 or 10 and including a branched alkyl group; B: sebacic acid; and C: an aromatic monobasic carboxylic acid having a total carbon number of 11 to 13. | 2013-08-01 |
20130196890 | STABLE, VISCOUS, PEROXIDE CONTAINING LAVATORY TREATMENT COMPOSITIONS - Provided is shelf stable, largely aqueous hard surface treatment composition which comprises at least water, at least one or more peroxygen compounds, and especially preferably wherein compositions comprise (or consist essentially of, or consist of): hydrogen peroxide, a betaine surfactant, an anionic surfactant, a water soluble or water dispersible metal salt, a chelating agent, an inorganic acid constituent, optionally a pH adjusting agent, and optionally one or more further constituents which provide a technical or aesthetic benefit to the inventive composition of which it forms a part. In preferred embodiments, the compositions are viscous, exhibiting a viscosity in the range of about 100-2000 cPs, preferably about 500-1200 cPs when measured at room temperature and exhibits a pH in the range of about 2 to about 4, preferably about 2.5-3.5. The treatment compositions are also characterized in that they contain no organic acids comprising less than three carboxylate (—COOH) moieties, and that the acid constituent is based on one or more inorganic acids, and preferably is a sulfonic acid. | 2013-08-01 |
20130196891 | Polyol Oxidases - The present invention provides compositions and methods for producing a polyol oxidase in micoroorganisms, and the use of polyol oxidases in cleaning compositions. The invention includes cleaning compositions that contain combinations of two or more POx oxidases, and cleaning compositions that contain combinations of two or more POx oxidases and a perhydrolase. In particular, the invention provides methods for expressing polyol oxidases in bacterial hosts for use in detergent applications for cleaning, bleaching and disinfecting. | 2013-08-01 |
20130196892 | PACKAGED PARTICULATE DETERGENT COMPOSITION - A packaged particulate detergent composition, wherein the composition comprises greater than 40 wt % detergent surfactant, at least 70% by number of the particles comprising a core, comprising mainly surfactant, and around the core, a water soluble coating in an amount of from 10 to 45 wt % based on the coated particle, each coated particle having perpendicular dimensions x, y and z, wherein x is from 0.2 to 2 mm, y is from 2.5 to 8 mm, and z is from 2.5 to 8 mm, the packaged particles being substantially the same shape and size as one another. | 2013-08-01 |
20130196893 | Hard Surface Cleaners Comprising Low VOC, Low Odor Alkanolamines - Hard surface cleaning compositions comprise: A. Surfactant, e.g., a nonionic ethoxylated alcohol; B. Solvent, e.g., propyleneglycol n-butyl ether; C. Low VOC, low odor, alkanolamine selected from the group consisting of tris(hydroxymethyl)amino methane; 2-amino-2-methyl-1,3-propanediol; 2-amino-2-ethyl-1,3-propanediol; 2-amino-2-methyl-1-propanol; N,N-dimethylamino-2-methyl-1-propanol; and 3-amino-4-octanol; D. Water, and E. Optionally, one or more of an alkaline agent, builder, fragrance, preservative, biocide, colorant, dye and rheology modifier. | 2013-08-01 |
20130196894 | Fabric Softener Active Composition - The present invention is directed to compositions that are characterized by the presence of ester quats with specific characteristics that promote dispersibility at low temperature. Among the important characteristics of the ester quats are an iodine value of 65-85 and distribution of: 33-38% monoesters, 50-55% diesters and 7-12% triesters. | 2013-08-01 |
20130196895 | LONG-LASTING FRAGRANCE DELIVERY SYSTEM - Long-lasting fragrance delivery systems and uses of the systems to provide fragrance-emitting articles with a long-lasting fragrance are disclosed herein. The long-lasting fragrance delivery systems include an emulsion of silicone-based polyurethane, fragrance, and a carrier. | 2013-08-01 |
20130196896 | CAR PEPTIDE FOR HOMING, DIAGNOSIS & TARGETED THERAPY FOR PULMONARY AND FIBROTIC DISORDERS - Disclosed are compositions and methods useful for delivering targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to effect a beneficial therapeutic result. The disclosed targeting is useful for delivering therapeutic and detectable agents to diseased tissue in an animal. | 2013-08-01 |
20130196897 | Glucosamine Pro-drug - To develop glucosamine (GlcN) pro-drugs with properties superior to the presently available GlcN products, we have synthesized derivatives with improved pharmaceutical properties. The synthesized derivatives include peptide-GlcN ester and amide conjugates where the peptide portion consists of one or more amino acids. One such compound is (5-amino-3,4,6-trihydroxyoxan-2-yl)methyl 2-(2-aminoacetamido)-3-methylbutanoate or glycine-valine-COO-GlcN (GV-GlcN).7 | 2013-08-01 |
20130196898 | TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN - The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups. | 2013-08-01 |
20130196899 | SYNTHETIC APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE - The invention provides a synthetic polypeptide of Formula I′: | 2013-08-01 |
20130196900 | ENHANCEMENT OF INNATE RESISTANCE TO INFECTION - The present invention provides compounds and compositions that enhance the innate immune system. The present invention comprises methods of preventing, treating or ameliorating an infectious disease comprising administering said compounds to a subject. The invention also comprises methods of formulation and administration of said compounds. | 2013-08-01 |
20130196901 | Neisseria Porin Protiens - PorA constructs are provided which have one or more disrupted variable regions created by insertion of entire conserved regions or conserved region amino acids. The highly immunogenic variable regions of PorA are responsible for eliciting strain-specific immune responses that are not broadly protective, so disruption of the variable regions directs the immune response against conserved region epitopes to effectively immunize against a broader spectrum of | 2013-08-01 |
20130196902 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof - This application describes compounds acting as, for example, β-arrestin effectors and uses thereof, in, for example, the treatment of chronic and acute cardiovascular diseases. | 2013-08-01 |
20130196903 | Multimeric Inhibitors of Viral Fusion and Uses Thereof - The present invention relates to novel multimeric inhibitors of viral entry into cells and their use for the prophylaxis and treatment of viral infections. | 2013-08-01 |
20130196904 | PHARMACEUTICAL COMPOSITION FOR TREATING MEDICAL CONDITIONS AND A METHOD FOR TREATING ALIMENTARY DISORDERS AND RELATED DISEASES - The present invention refers to a pharmaceutical compositions that comprises an active ingredient, such as a peptide, which acts as an antagonist and/or inverse agonist of a G protein-coupled receptor and pharmaceutically acceptable vehicle. Said pharmaceutical composition may be used for the treatment of obesity and the prevention of and the treatment of diabetes | 2013-08-01 |
20130196905 | USE OF GLYCOMACROPEPTIDE TO IMPROVE WOMEN'S HEALTH - Methods for improving the health of a female human or non-human animal are disclosed. The methods include the step of administering to the animal compositions including an effective amount of glycomacropeptide (GMP) for effectuating the methods. Specifically, the methods can be used to increase the rate of fat metabolism or fat oxidation, decrease percentage of body fat, increase the rate of bone mineralization, increase bone mineral content, increase bone mineral density, and/or increase bone strength in the animal. | 2013-08-01 |
20130196906 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates. | 2013-08-01 |
20130196907 | Promoting Erythropoietin, Erythrocyte, and Hematopoietic Stem Cell Production By Activating HIF In OsteoBlasts - Methods are provided for promoting the production of erythropoietin and the production of erythrocytes and hematopoietic stem and progenitor cells. These methods find us in the treatment of subjects with conditions in which erythrocyte cell numbers are reduced, for example, anemia, chronic kidney disease, and following chemotherapy treatment. | 2013-08-01 |
20130196908 | METHODS FOR TREATMENT OF PAIN - The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects. | 2013-08-01 |
20130196909 | BMP-7 Peptides and Methods of Use - The invention relates to truncated growth factors and variants thereof. The invention also relate to methods of making and using the truncated growth factors. | 2013-08-01 |
20130196910 | BMP-4 PEPTIDES AND METHODS OF USE - The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. | 2013-08-01 |
20130196911 | METHODS AND COMPOSITIONS FOR CARDIOPROTECTION AND CARDIOREGENERATION - The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, such as neuregulin dimers, that selectively induce the dimerization of certain EGF receptors in cardiac tissue. | 2013-08-01 |
20130196912 | BETA THYMOSIN FRAGMENTS - Peptide fragments having amino acid sequences corresponding to portions of a thymosin beta 4, a thymosin beta 10 and/or a thymosin beta 15 amino acid sequence are provided, as well as methods of treatment utilizing same. | 2013-08-01 |
20130196913 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 2013-08-01 |
20130196914 | Methods for Chronic Pain Management and Treatment using HCG - A gonadotropin is administered within a surprisingly effective narrow range for the purpose of treating chronic pain or other central sensitization sequelae. In one aspect, a recipient is provided with at least one of human chorionic gonadotropin (uHCG and/or rHCG), a pharmaceutically active HCG analogue, and a pharmaceutically active metabolite of the HCG or analogue at a dosage selected to provide, or be equivalent to, a human subcutaneous dosage of between 120 IU/day and 170 IU/day of HCG, and more preferably between 140 IU/day and 160 IU/day of HCG. A kit is also described, which includes a supply of the HCG-related drug, a delivery device, and a label that identifies chronic pain or central sensitization as an indication of the drug. | 2013-08-01 |
20130196915 | AFFINITY HYDROGELS FOR CONTROLLED PROTEIN RELEASE - The present invention relates to novel porous matrix composites and formulations for controlled protein delivery and the uses therefor. The present invention also provides methods of synthesizing such protein delivery systems. The composites comprise affinity sites embedded in the matrix where the affinity sites are functionalized with nucleic acid aptamers having high affinity for proteins to be released. The aptamers function as binding affinity sites for the proteins to be released. In certain embodiments, release rates are controlled by tuning the binding affinity of the nucleic acid aptamers to the proteins at a desired level. In yet other embodiments, complementary oligonucleotides that hybridize with the aptamers are employed to trigger accelerated release of the proteins when desired. Various in situ injectable hydro gels functionalized with aptamers are provided for treating a condition and disease in a subject in need of a therapeutic protein. | 2013-08-01 |
20130196916 | PROCESS FOR PRODUCTION OF BIVALIRUDIN - The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp | 2013-08-01 |
20130196917 | PROCESS FOR PRODUCTION OF BIVALIRUDIN - The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp | 2013-08-01 |
20130196918 | PROCESS FOR PRODUCTION OF BIVALIRUDIN - The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp | 2013-08-01 |
20130196919 | PROCESS FOR PRODUCTION OF BIVALIRUDIN - The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp | 2013-08-01 |
20130196920 | PROCESS FOR PRODUCTION OF BIVALIRUDIN - The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp | 2013-08-01 |
20130196921 | METHODS FOR THE PREVENTION OR TREATMENT OF NO-REFLOW FOLLOWING ISCHEMIA/REPERFUSION INJURY - The invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods provide administering aromatic-cationic peptides in effective amounts to prevent or treat an anatomic zone of no re-flow in mammalian subjects. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 2013-08-01 |
20130196922 | BNIP3 ISOFORMS AND METHODS OF USE - The present invention provides isolated splice variants of Bnip3 and isolated polynucleotides encoding the splice variants. Also provided are isolated polypeptides present at the carboxy-terminus of Bnip3 splice variants, and antibody that specifically binds Bnip3 splice variants and/or the carboxy-terminus of Bnip3 splice variants. The present invention further provides methods of altering cellular apoptosis, cellular necrosis, cellular autophagy, or the combination thereof. For instance, the methods may include changing the amount of a Bnip3 splice variant or a carboxy-terminal region of a Bnip3 splice variant in a cell. Also provided herein are methods for determining whether death of cells in a tissue can be altered, methods for evaluating treatment options for a subject, and methods for identifying a compound that alters the amount or activity of a Bnip3 splice variant in a cell. | 2013-08-01 |
20130196923 | NOVEL PEPTIDES WHICH HAVE ANALGESIC EFFECTS AND WHICH INHIBIT ASIC CHANNELS - The present invention relates to novel isolated peptides which induce analgesia and which inhibit ASIC channels (Acid Sensing Ion Channels), to the polynucleotides encoding said peptides, and also to the pharmaceutical compositions, host cells and vectors comprising same. In particular, said peptides are isolated from the venom of the snake | 2013-08-01 |
20130196924 | BIOMARKERS FOR DIAGNOSING AND DETECTING THE PROGRESSION OF NEURODEGENERATIVE DISORDERS, IN PARTICULAR OF AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to biomarkers, to their use and to a method for diagnosing in vitro or detecting the progression of a neurodegenerative disease in an individual, in particular for Amyotrophic Lateral Sclerosis (ALS). The method comprises the steps of isolating a biological sample from the individual; quantifying the level of one or more polypeptides in the biological sample according to the invention; comparing the obtained level with a reference level. | 2013-08-01 |
20130196925 | COMPOSITIONS AND METHODS USEFUL IN ENHANCEMENT OF MEMORY - Compounds derived from a transduction complex that enhance memory in mammals and methods of enhancing memory using said compounds are disclosed. | 2013-08-01 |
20130196926 | CONTROLLED RELEASE OF OCULAR BIOPHARMACEUTICALS USING BIORESPONSIVE PROTEIN POLYMERS - Described herein are bioresponsive protein polymers for therapeutic applications, including delivery to physiologically demanding environments, such as the eye surface. Bioresponsive protein polymers can be fused with biopharmaceuticals using genetic engineering techniques for enhanced therapeutic activity. In certain embodiments, the unique temperature-sensitive phase separation properties of bioresponsive protein polymers, allows generation of therapeutics resistant to ocular clearance. Such fusion proteins containing bioresponsive protein polymers and biopharmaceuticals allow retention of drugs in the eye for much longer periods of time. Improved biostability and bioavailability improves drug efficacy, while reducing cost and eliminating the need for repeated drug application | 2013-08-01 |
20130196927 | Smac Mimetic Therapy - A Smac mimetic therapy wherein the Smac mimetic is selected and developed based at least in part on its cIAP degradation properties. | 2013-08-01 |
20130196928 | LIBRARY FROM TOXIN MUTANTS AND METHODS OF USING SAME - This application relates to ABx toxin mutants and libraries of said mutant proteins, in which a peptide insert is introduced into the protease-sensitive loop of the A-chain sequence to alter the type of cells to which toxic species are delivered. Said libraries are used in the development of therapeutics targeted against specific cell types. | 2013-08-01 |
20130196929 | SECRETED PROTEIN ACIDIC AND RICH IN CYSTEINE (SPARC) AS CHEMOTHERAPEUTIC SENSITIZERS - The present invention relates to compositions and methods of use thereof for cancer therapy sensitization. Such compositions comprise functional fragments of the nucleotide and/or polypeptide sequences of a Secreted Protein Acidic and Rich in Cysteine (SPARC). The compositions can be used in combination with existing chemotherapeutic agents for treatment of cancers. | 2013-08-01 |
20130196930 | POLYNUCLEOTIDES ENCODING RECOMBINANT LUBRICIN MOLECULES AND USES THEREOF - Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided. | 2013-08-01 |
20130196931 | MEANS AND METHODS FOR COUNTERACTING PROTEIN AGGREGATION - The invention provides a use of a substance that is capable of enhancing the amount and/or activity of DnaJB8, or a functional part, derivative and/or analogue thereof, for counteracting protein aggregation. | 2013-08-01 |
20130196932 | Frataxin Mutants - Described herein are compositions and methods for treating Friedreich's Ataxia (FRDA). In some aspects, mutant forms of frataxin which are resistant to ubiquitination are provided. In some aspects, pharmaceutical compositions comprising mutant frataxin are provided. In further aspects, methods of using mutant frataxin are provided. | 2013-08-01 |
20130196933 | Methods and Compositions Inhibiting Tumor Cell Proliferation - The invention provides agents, compositions, pharmaceutical compositions and method for inhibiting tumor cell proliferation by inhibiting FoxM1B activity, expression, or nuclear localization in a tumor cell. | 2013-08-01 |
20130196934 | COMPOSITION FOR PERINATAL AND NEONATAL STROKE - The present invention relates to a novel, non-toxic, prophylactic maternal nutraceutical composition for prevention, treatment, minimization or amelioration of brain damage from perinatal and/or neonatal stroke. | 2013-08-01 |
20130196935 | SYNTHETIC GLYCOAMINE COMPOUNDS - This disclosure is directed to synthetic glycoamine compounds and pharmaceutical compositions containing such compounds. The synthetic glycoamine compounds provided here can affect cell adhesion and induce apoptosis, and are useful in treating metastatic diseases and cancer. | 2013-08-01 |
20130196936 | N-ACETYL MANNOSAMINE AS A THERAPEUTIC AGENT - The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine. | 2013-08-01 |
20130196937 | AGE PRODUCTION INHIBITOR - Disclosed is an AGE production inhibitor or the like, which effectively inhibits the production of an advanced glycation end product (AGE), while having improved biological safety. Specifically disclosed is an AGE production inhibitor or the like, which contains en extract of cherry tree (preferably blossoms or leaves thereof) and/or a processed product of the extract as an active substance. The AGE production inhibitor or the like contains, as an active substance, at least one compound that is selected from among 1-O-(E)-Caffeoyl-β-D-glucopyranoside, 1-O-(E)-Coumaroyl-β-D-glucopyranoside, 1-O-(E)-Cinnamoyl-β-D-glucopyranoside, Kaempferol 3-O-β-D-glucopyranoside, Quercetin 3-O-β-D-glucopyranoside, Kaempferol 3-O-(6″-malony)-β-D-glucopyranoside, and Quercetin 3-O-(6″-malony)-β-D-glucopyranoside. | 2013-08-01 |
20130196938 | COMBINATION COMPRISING CNDAC (2'-CYANO-2'-DEOXY-N4-PALMITOYL-1-BETA-D-ARABINOFURANOSYL-CYTOSINE) AND A CYTOTOXIC AGENT - A first aspect of the invention relates to a combination comprising 2′-cyano-2′-deoxy-N | 2013-08-01 |
20130196939 | DETECTION OF DNA SEQUENCES AS RISK FACTORS FOR HIV INFECTION - A method for identifying a risk factor for diseases, disorders or conditions, such as those caused by human immunodeficiency virus, using the polymerase chain reaction and specific primers. Methods for treating patients having these diseases, disorders or conditions by antimicrobial treatment of the risk factor by combined antiviral and antibacterial treatment or by sustaining or stimulating the subject's immune system. Methods for screening biological products including red blood cell preparations. Primers and methods for detecting nucleic acids or microbial agents associated with red blood cells, such as those associated with red blood cells in subjects infected with HIV and undergoing antiretroviral therapy. | 2013-08-01 |
20130196940 | ANHYDROUS POLYMORPHS OF [(2R,3S,4R,5R)-5-(6-(CYCLOPENTYLAMINO)-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAH- YDROFURAN-2-YL)} METHYL NITRATE AND PROCESSES OF PREPARATION THEREOF - The present invention provides novel anhydrous polymorph forms of 2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate (Compound A). The present invention also provides processes for preparation of the anhydrous polymorphic forms of compound A. | 2013-08-01 |
20130196941 | PARENTERAL FORMULATIONS OF ELACYTARABINE DERIVATIVES - The present invention relates to parenteral formulations for certain long chain saturated and monounsaturated fatty acid derivatives of 1-β-D-arabinofuranosylcytosine (cytarabine). In particular, the present invention relates to a parenteral pharmaceutical composition and a method of the preparation thereof, in order to accommodate therapeutically effective doses of the said derivatives ameliorating compliance in treatment of cancer. | 2013-08-01 |
20130196942 | Composition for Skin Treatment - A composition comprising from 10 to 15% by weight of sucrose palmitate. The composition can be used to treat eczema. | 2013-08-01 |
20130196943 | NOVEL CHONDROITIN SULFATE HAVING DECREASED MOLECULAR WEIGHT AND USE THEREOF - A chondroitin sulfate having a decreased molecular weight which has utilization as an inhibitor of peritoneal disorder caused by long-term use of a peritoneal dialysis fluid containing glucose or a polysaccharide thereof as an osmotic agent, utilization as an osmotic agent in a peritoneal dialysis fluid, and the like. The chondroitin sulfate having a decreased molecular weight of the present invention as a means for achieving the object is characterized by having a weight average molecular weight of from 1000 to 20000 and containing a constituent disaccharide unit represented by the following structural formula in an amount of from 65% to 100% (molar ratio) of the total: | 2013-08-01 |
20130196944 | FILLER COMPOSITION COMPRISING BETA-GLUCANS - The present invention pertains to a filler composition comprising β-glucan moieties and optionally a cosmetically and/or pharmaceutically acceptable carrier. It further relates to a filler composition, wherein the β-glucan moieties are cross-linked. in one embodiment of the instant invention the filler composition is a dermal filler. In one further embodiment of the present invention the filler composition is for the treatment of wrinkles and/or folds. In another embodiment of the instant invention the filler composition is for use in the treatment of a medical condition. The filler composition provided in the present invention may further comprise one or more active pharmaceutical ingredients. Further, the present invention pertains to a process for preparing the filler composition as claimed herein. | 2013-08-01 |
20130196945 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. | 2013-08-01 |
20130196946 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-taxane conjugates are described herein. | 2013-08-01 |
20130196947 | USE OF CYCLODEXTRIN FOR TREATMENT AND PREVENTION OF BRONCHIAL INFLAMMATORY DISEASES - The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma and chronic obstructive pulmonary disease (COPD). | 2013-08-01 |
20130196948 | POLYMERS FOR BIOMATERIALS AND THERAPEUTICS - Described herein are inventive compositions and methods relating to polymer conjugates and, in particular, to polymer conjugates having pendant side groups comprising ring moieties. In one aspect, embodiments are generally related to compositions that mimic naturally-occurring polyphenol compounds. The compositions comprise, in some embodiments, a polymer backbone having a plurality of hydroxyaromatic pendant side groups or derivatives thereof. For example, in some cases, a pendant side group may be a phenol or a substituted derivative thereof. In some cases, the pendant side group may be an oxidized hydroxyaromatic group, such as a quinone. In some embodiments, self-assembled structures comprising one or more of the polymer conjugates are provided. For example, the polymer conjugates may be combined with a complexing agent to form a particle. In some cases, a polymer conjugate may form a hydrogel. In some embodiments, the self-assembled structures may contain an agent, such as a pharmaceutically active agent. Also provided are methods and kits for forming the compositions, methods of using the compositions, and the like. | 2013-08-01 |
20130196949 | Hydroxyalkyl starch in combination with cytostatica for the treatment of cancers by reduction of tumor growth rates - The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of cancer, tumor or tumor associated diseases, especially by effectively reducing tumor growth rate and inhibiting tumor growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted. | 2013-08-01 |
20130196950 | RETINOID REPLACEMENTS AND OPSIN AGONISTS AND METHODS FOR THE USE THEREOF - Compositions of and methods for using synthetic retinoids as retinoid replacements and opsin agonists are provided. | 2013-08-01 |
20130196951 | USE OF NITRIC OXIDE TO ENHANCE THE EFFICACY OF SILVER AND OTHER TOPICAL WOUND CARE AGENTS - The present invention is directed to compositions comprising at least one nitric oxide donor and at least one second therapeutically active agent with antimicrobial or wound healing capability. In one embodiment, the nitric oxide donor is a nanoparticle which is designed to control for the amount and duration of release of nitric oxide. The nanoparticle may further comprise the additional therapeutically active agent. The composition is useful for enhancing wound healing and for treating and preventing microbial infection. In one embodiment, the composition is directed toward reducing oral bacteria or dental plaque. The combination of one or more nitric oxide donors and one or more additional therapeutically active agent results in unexpected synergistic effects, wherein both the antimicrobial efficacy of the nitric oxide and the antimicrobial or wound healing efficacy of the second therapeutically active agent are enhanced. As a result, a patient may benefit from reduced dosage requirements and a reduced likelihood of antimicrobial resistance. The composition may be formulated for local or systemic administration, for topical applications as well as for use in coatings for medical supplies and devices. | 2013-08-01 |
20130196952 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES - The invention relates to compounds of Formula (1) and to processes for the preparation of intermediates used in the preparation of compositions containing and the uses of such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein. | 2013-08-01 |
20130196953 | GENES FOR BIOSYNTHESIS OF TETRACYCLINE COMPOUNDS AND USES THEREOF - The invention relates to tetracycline products produced by genetically engineered cells, and to therapeutic methods using such tetracyclines. The present invention is based on the cloning and heterologous expression of genes encoding the chelocardin biosynthetic pathway. | 2013-08-01 |
20130196954 | METHOD OF TREATING ACNE - An improved method for treating acne is described. The method involves 16-week, once daily, oral administration of about 40 mg doxycycline in a pharmaceutical composition containing about 30 mg doxycycline in an immediate release portion and about 10 mg doxycycline in a delayed release portion. It was surprisingly discovered that the 16-week, once daily, oral administration of about 40 mg doxycycline has achieved same or superior efficacy than that of 100 mg doxycycline, but with a significant reduction in adverse events. | 2013-08-01 |
20130196955 | POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME - The invention provides compositions and methods for determining the increased risk for recurrence of certain cancers and the likelihood of successful treatment with one or both of chemotherapy and radiation therapy. The methods comprising determining the type of genomic polymorphism present in a predetermined region of the gene of interest isolated from the subject or patient. Also provided are nucleic acid probes and kits for determining a patient's cancer risk and treatment response. | 2013-08-01 |
20130196957 | ROLL-ON WITH HIGH SALICYLIC ACID CONTENT - The present invention relates to an assembly ( | 2013-08-01 |
20130196958 | METHODS OF NOURISHING ANIMALS - The present invention relates to methods of maintaining, and methods of restoring, a desired calcium homeostasis in a non-human terrestrial animal by administering an effective amount of one or more Calcium-Sensing Receptor modulators (CaSRs) to the animal. The invention further provides methods of reducing foot lesions in chickens. The invention also relates to food compositions useful in the methods of the invention. | 2013-08-01 |
20130196959 | TOPICAL STEROIDAL FORMULATIONS - The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome. | 2013-08-01 |
20130196960 | Cannabinoid Receptor Agonists - The present disclosure relates to compounds useful as agonists of cannabinoid receptors. The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment of various disorders either alone or in combination therapy. The compounds have Formula (I), or are pharmaceutically acceptable salts thereof: | 2013-08-01 |
20130196961 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS - A combination which comprises (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid. | 2013-08-01 |
20130196962 | NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy. | 2013-08-01 |
20130196963 | TOPICAL STEROIDAL FORMULATIONS - The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome. | 2013-08-01 |